As of Jan 20
| +0.05 / +0.21%|
The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 24.00 and a low estimate of 14.00. The median estimate represents a +1.05% increase from the last price of 23.75.
The current consensus among 9 polled investment analysts is to Hold stock in ARIAD Pharmaceuticals Inc. This rating has held steady since January, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.